PTC Therapeutics(PTCT) Stock Price Today

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

PTCT PTC Therapeutics

Watchlist

51.920
-0.570-1.09%

Trading Mar 11 09:59 ET

4.09BMarket Cap-10.98P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

PTC Therapeutics Raised to Neutral From Underperform by B of A Securities
Dow Jones05:40 ET · Ratings
BofA Securities Upgrades PTC Therapeutics(PTCT.US) to Hold Rating, Raises Target Price to $55
Moomoo News18:31 ET · Ratings
Express News | Form 144 | PTC Therapeutics(PTCT.US) Officer Proposes to Sell 3.61 Million in Common Stocks
Moomoo News16:29 ET
Scotiabank Initiates Coverage On PTC Therapeutics With Sector Perform Rating, Announces Price Target of $55
BenzingaMar 7 17:39 ET · Ratings
PTC Therapeutics Coverage Assumed by Morgan Stanley at Overweight
Dow JonesMar 7 12:51 ET
Morgan Stanley Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $70
Moomoo NewsMar 7 09:31 ET · Ratings

Comments

Teddy123

Feb 19 06:27

PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia

$PTC Therapeutics (PTCT.US)$
Could This Rare Disease Drug Be PTC's Next Breakthrough? FDA Priority Review Reveals Major Potential

Lnova

Dec 19, 2024 17:24

$PTC Therapeutics (PTCT.US)$
PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia
12/19/2024 08:00AM ET
- If approved, vatiquinone would be the first and only authorized therapy for children with FA -
- PTC's fourth approval application submitted to FDA in 2024 -
WARREN, N.J., Dec. 19, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the submission of the vatiquinone New Drug Application (NDA) ...

Meltyy

May 22, 2024 02:52

Biotech Stock Catalyst Watchlist 👀

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...

mad541

May 20, 2024 07:38

$PTC Therapeutics (PTCT.US)$ just dud offering 22.87 a share get out 🔻🔻🔻🔻

Moomoo AI

Mar 3, 2024 08:56

PTC Therapeutics' low P/S ratio is seen as reasonable due to industry underperformance. However, weak revenue outlook is pressuring shares, making maintaining current prices challenging. Shareholders accept the low P/S, expecting no future revenue surprises.